Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer

A triple-negative breast cancer, reverse transcription technology, applied in the field of breast cancer diagnosis, can solve problems such as limitations, poor prognosis, and strong invasiveness

Active Publication Date: 2017-12-15
SUN YAT SEN UNIV CANCER CENT
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical characteristics of triple-negative breast cancer are not only strong invasiveness, high histological grade, poor prognosis, and susceptibility to visceral metastasis, but also the lack of corresponding targets for endocrine therapy and molecular targeted therapy targeting HER-2, and the choice of treatment methods Restricted relative to other molecular subtypes of breast cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer
  • RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer
  • RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0047] specific implementation

[0048] The present invention will be further described in detail below in combination with specific embodiments, so as to help those skilled in the art understand the present invention.

[0049] 1. Composition of triple negative breast cancer tissue diagnostic kit (50 reactions)

[0050] 100ml of isopropanol, 100ml of chloroform, 50ml of Trizol, 10ml of DEPC water or enzyme-free water, 10ml of double distilled water, 1ml of 5× reverse transcription buffer, 1ml of 25mM magnesium chloride, 1ml of 10mM base triphosphate deoxynucleotide, 5U / μl RAN enzyme inhibitor 500μl, 200U / μl MMLV reverse transcriptase 50μl or 25U / μl AMV enzyme 50μl, 2× real-time quantitative PCR buffer 2ml, 5U / μl Taq polymerase 50μl,

[0051] 5 μM circEPSTI1 specific PCR primer 50 μl,

[0052] The forward primer is 5′-AAGCTGAAGAAGCTGAACTC 3′,

[0053] Its reverse primer is 5'-GTGTATGCACTTGTGTATTGC-3'.

[0054] 5μM β-actin specific PCR primer 30μl

[0055] The forward pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of breast cancer diagnosis, and specifically discloses RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer. The application of the RNA circEPSTI1 in the triple negative breast cancer comprises the following steps: firstly, collecting a to-be-detected suspected triple negative breast cancer tissue sample, extracting total RNA, specifically and reversely transcribing the cyclic RNA circEPSTI1 (hsa_circRNA_000479) into cDNA (Complementary Deoxyribonucleic Acid) by using the total RNA as a template; carrying out real-time quantitative PCR (Polymerase Chain Reaction) amplification by using a specific PCR primer; using beta-actin as a reference gene, thus obtaining a relative quantitative deltaCT value of circEPSTI1; reminding that the circEPSTI1 is in positive expression when deltaCT is smaller than or equal to 5.52. According to the RNA circEPSTI1 and the application thereof in the triple negative breast cancer, disclosed by the invention, the RNA circEPSTI1 is applied to prognostic prediction of a triple negative breast cancer patient through relatively and quantitatively detecting the expression situation of the circEPSTI1 in the suspected triple negative breast cancer tissue sample.

Description

technical field [0001] The invention relates to the technical field of breast cancer diagnosis, and specifically discloses a small molecule non-coding circular RNA circEPSTI1 and its application in triple-negative breast cancer. Background technique [0002] Breast cancer is the female malignancy with the highest incidence rate in the world. As a country with a large population and a unique aging society, the incidence of breast cancer in China is growing faster than other countries, and the situation is not optimistic. Breast cancer has not been fully and effectively controlled so far, and breast cancer still presents a high mortality rate, mainly due to its recurrence and metastasis. Once breast cancer metastasizes, the average survival rate is only about 4-5 years. Triple-negative breast cancer refers to breast cancer with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2), accounting for 15% of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 谢小明唐海林陈博韦尉东谢新华刘鹏叶锋杨露黄晓嘉宋彩露
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com